RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.

Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B, Wu X, Wan G. · 2019

Read RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. by Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B, Wu X, Wan G. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6437932.txt.

Introduction

Niu and co-authors show that FTO, an enzyme that strips m6A marks from RNA, drives breast cancer growth by silencing the protective gene BNIP3. FTO levels ran high in human breast tumors, and patients with more of it survived less often. Experiments used three breast cancer cell lines plus 36 primary tumors and 12 neighboring tissues.

Sequencing of marked RNA pinpointed BNIP3, a gene that promotes cell death, as FTO's target. FTO removed marks from BNIP3 messenger RNA and triggered its decay, freeing cancer cells to multiply, form colonies, and spread in animals. Restoring BNIP3 largely cancelled those effects. Blocking FTO is proposed as a new treatment strategy.

Catalog record

CREATORNiu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B, Wu X, Wan G.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6437932

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3 By Yi Niu, Ziyou Lin, Arabella Wan, Honglei Chen, Heng Liang, Lei Sun, Yuan Wang, Xi Li, Xiao-feng Xiong, Bo Wei, Xiaobin Wu, Guohui Wan Published in: Molecular Cancer DOI: 10.1186/s12943-019-1004-4 ABSTRACT Background N6-methyladenosine (m6A) modification is the most pervasive modification in mRNA, and has been considered as a new layer of epigenetic regulation on mRNA processing, stability and translation. Despite its functional significance in various physiological processes, the role of the m6A modification involved in breast cancer is yet fully understood. Methods We used the m6A-RNA immunoprecipitation sequencing to identify the potential targets in breast cancer. To determine the underlying mechanism for the axis of FTO-BNIP3, we performed a series of in vitro and in vivo assays in 3 breast cancer cell lines and 36 primary breast tumor tissues and 12 adjunct tissues. Results We showed that FTO, a key m6A demethylase, was up-regulated in human breast cancer. High level of FTO was significantly associated with lower survival rates in patients with breast cancer. FTO promoted breast cancer cell proliferation, colony formation and metastasis in vitro and in vivo. We identified BNIP3, a pro-apoptosis gene, as a downstream target of FTO-mediated m6A modification. Epigenetically, FTO mediated m6A demethylation in the 3’UTR of BNIP3 mRNA and induced its degradation via an YTHDF2 independent mechanism. BNIP3 acts as a tumor suppressor and is negatively correlated with FTO expression in clinical breast cancer patients. BNIP3 dramatically alleviated FTO-dependent tumor growth retardation and metastasis. Conclusions Our findings demonstrate the functional significance of the m6A modification in breast cancer, and suggest that FTO may serve as a novel potential therapeutic target for breast cancer. Electronic supplementary material The online version of this article (10.1186/s12943-019-1004-4) contains supplementary material, which is available to authorized users. BACKGROUND Breast cancer continues to be a severe threat towards women in the world. It is estimated that more than 2.1 million new cases of breast cancer occurred in 2018, causing 627,000 death in women [1]. With the advent of molecular classification in breast cancer, the 5-year survival rate for patients diagnosed with localized tumors reached 90%, however, for those patient diagnosed with advanced tumors, the 5-year survival rate was less than 30% [2]. The mortality from breast cancer was primarily due to chemo-resistance and metastasis. Administration of novel target intervention may help to prevent initial or aggressive metastasis, thereby improving survival and clinical outcomes for patients with advanced breast tumors. While global gene expression patterns of breast cancer have been extensively studied, post-transcriptional regulation of gene expression involved in advanced breast tumors has yet fully investigated. Examining post-transcriptional gene regulation can better understand the molecular mechanism of breast cancer, providing a more comprehensive picture of the biology of cancer progression. N6-methyladenosine (m6A) modification is the methylation of the adenosine base at the nitrogen-6 position of mRNA. The m6A modification is the most pervasive internal modification of mRNA in mammalian cells, with wide distribute (> 25%) abundance in the transcripts [3, 4]. Unlike other modifications of mRNA, the m6A modification is dynamically reversible as the DNA and histone modifications [5], and plays an critical role in regulating precursor mRNA maturation, translation and degradation [3, 6, 7]. The m6A modification is mainly mediated by the methyltransferase (METTL3, METTL14 and WTAP) [8–10], demethylase (FTO and ALKBH5) [5, 11] and proteins that preferentially recognized m6A methylated transcripts (YTH domain family proteins [12–16], HNRNPA2B1 [17] and IGF2BP [18]). The m6A modification was found to regulate stem cell differentiation and self-renewal through affecting mRNA turnover during cell differentiation and embryonic development [19, 20]. Emergent evidence has shown that the m6A modification plays an important role in the occurrence and development of various human diseases [21–24]. FTO was the first m6A demethylase to show m6A demethylation activity on mRNA and catalyze m6A demethylation in a ferrous iron dependent manner [5]. Previously, FTO was known to be highly associated with increased body mass and obesity in childhood and adult [25, 26]. FTO-knockout mice showed protection from obesity but caused growth failure [27]. Recently, FTO was shown to mediate mRNA processing of adipogenetic regulatory factors in adipogenesis by m6A demethylation [28]. Chen and He groups showed an oncogenic role of FTO in acute myeloid leukemia (AML) [29]. They found that FTO was high expressed in AML and inhibited ASB2 and RARA by reducing their m6A methylated level in the transcripts, resulting in enhancement of cell transformation and leukemogenesis [29]. The elevated level of FTO was also found in cervical squamous cell carcinoma (CSCC) and glioblastoma [30, 31]. Inactivation of FTO in leukemia induced sensitivity of resistance cells to tyrosine kinase inhibitor [32], indicating that the FTO-m6A axis may serve as novel potential therapeutic target in human cancers [33]. However, the underlying epigenetic regulation of FTO, as m6A demethylase, in breast cancer initiation and progression has yet to be investigated. In the present study, we sought to determine the role of m6A modification in breast cancer, and investigated the underlying molecular mechanism by which the m6A modification affects the initiation and progression of breast cancer. We first detected the levels of the m6A modification in breast cancer, and observed that FTO was up-regulated in human breast cancer tissues. Next, we demonstrated that silence of FTO could significantly reduce breast cancer cell proliferation, colony formation and enhance cell apoptosis. Further, we identified that BNIP3, a pro-apoptotic member of the Bcl-2 family of apoptotic proteins [34], was the target gene of FTO in mediating breast cancer proliferation and progression. We found that silencing BNIP3 could significantly alleviate FTO-dependent tumor growth retardation in vitro and in vivo. Based on the data, we revealed the important role of m6A modification mediated by FTO in breast cancer, and proposed that FTO may act as a novel therapeutic target in breast cancer progression. METHODS Breast cancer patient samples, cell lines and cell culture The breast tumor and normal tissues were obtained at the Third Affiliated Hospital of Sun Yat-Sen University and were approved by the institutional review board of the hospital. The study is compliant with all relevant ethical regulations regarding research involving human participants. For fresh tissues, breast tumors and adjacent normal tissues were separately dissected at the time of surgery and immediately transferred to RNAlater (R0901, Sigma). The paraffin-embedded specimens were collected from at the Eighth Affiliated Hospital of Sun Yat-Sen University. Breast cancer cell lines MDA-MB-231, MCF-7 and 4 T1 were obtained from American Type Culture Collection (ATCC) with authentication. These cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Corning, USA) with 10% fetal bovine serum (Gibco, USA) and antibiotics (Gibco, USA). Cells were grown in a 5% CO2 cell culture incubator at 37 °C. Plasmid constructions, cell transfection, and infection Stable knockdown of target genes was achieved by lentiviral-based short-hairpin RNA (shRNA) delivery. PLKO.1 vector with anti-puromycin or anti-hygromycin plasmid was constructed by using the primer sequences listed in Additional file 1: Table S1. For YTHDF2 overexpressing system, YTHDF2 cDNA (NM_016258) was cloned into pCDH puro lentiviral vector (CD510B-1, System Biosciences), For shRNA knockdown and overexpression, pLKO.1 and pCDH constructs together with packing and helper plasmids PAX2 and MD2G were co-transfected into 293 T cells by Calcium Phosphate Transfection

Read the complete text